Cytokinetics Announces New Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2016
November 07 2016 - 4:00PM
Cytokinetics, (Nasdaq:CYTK) today announced that a new analysis of
left atrial structure and function from COSMIC-HF (Chronic Oral
Study of Myosin Activation to Increase Contractility in Heart
Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients
with chronic heart failure, will be presented on November 14 at the
American Heart Association (AHA) Scientific Sessions in New
Orleans, LA.
Abstract Title: Cardiac Myosin Activator
Omecamtiv Mecarbil Improves Left Atrial Structure and Function in
Chronic Heart Failure (COSMIC-HF)Abstract Number: M 4180Session
Title: Impact of Novel Therapies on Cardiac Structure and
FunctionLocation: Science and Technology Hall, Clinical Science
SectionDate: Monday, November 14, 2016Time: 2:00 – 3:15 PM
About Omecamtiv Mecarbil
Omecamtiv mecarbil is a novel cardiac
myosin activator. Cardiac myosin is the cytoskeletal motor protein
in the cardiac muscle cell that is directly responsible for
converting chemical energy into the mechanical force resulting in
cardiac contraction. Cardiac myosin activators are thought to
accelerate the rate-limiting step of the myosin enzymatic cycle and
shift the enzymatic cycle in favor of the force-producing state.
Preclinical research has shown that cardiac myosin activators
increase contractility in the absence of changes in intracellular
calcium in cardiac myocytes.
Omecamtiv mecarbil is being developed
by Amgen in collaboration
with Cytokinetics. Amgen holds an exclusive, worldwide
license to omecamtiv mecarbil and related compounds,
subject to Cytokinetics’ specified development and
commercialization rights. Amgen has granted a sublicense to Servier
to commercialize omecamtiv mecarbil in Europe, as well as the
Commonwealth of Independent States, including Russia.
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators as potential
treatments for debilitating diseases in which muscle performance is
compromised and/or declining. As a leader in muscle biology and the
mechanics of muscle performance, the company is developing small
molecule drug candidates specifically engineered to increase muscle
function and contractility. Cytokinetics’ lead drug candidate
is tirasemtiv, a fast skeletal muscle troponin activator, for
the potential treatment of ALS. Tirasemtiv has been
granted orphan drug designation and fast track status by
the U.S. Food and Drug Administration and orphan
medicinal product designation by the European Medicines
Agency for the potential treatment of
ALS. Cytokinetics retains the right to develop and
commercialize tirasemtiv, subject to an option held
by Astellas Pharma Inc. Cytokinetics is also
collaborating with Astellas to develop CK-2127107, a fast skeletal
muscle activator, for the potential treatment of spinal muscular
atrophy, chronic obstructive pulmonary disease and
ALS. Cytokinetics is collaborating with Amgen
Inc. to develop omecamtiv mecarbil, a novel cardiac
muscle activator, for the potential treatment of heart
failure. Amgen holds an exclusive license worldwide to
develop and commercialize omecamtiv mecarbil and Astellas
holds an exclusive license worldwide to develop and commercialize
CK-2127107. Both licenses are subject
to Cytokinetics' specified development and
commercialization participation rights. For additional information
about Cytokinetics, visit http://www.cytokinetics.com/.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Act’s Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to Cytokinetics’ and
its partners’ research and development activities, including the
significance and utility of COSMIC-HF clinical trial results and
the likelihood and timing for the progression of omecamtiv
mecarbil to Phase 3 development; and the properties and
potential benefits of Cytokinetics' drug candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited
to Amgen's decisions with respect to the design,
initiation, conduct, timing and continuation of development
activities for omecamtiv mecarbil; potential difficulties or
delays in the development, testing, regulatory approvals for trial
commencement, progression or product sale or manufacturing, or
production of Cytokinetics' drug candidates that could
slow or prevent clinical development or product approval, including
risks that patient enrollment for or conduct of clinical trials may
be difficult or delayed, Cytokinetics' drug candidates
may have adverse side effects or inadequate therapeutic efficacy,
the U.S. Food and Drug Administration or foreign
regulatory agencies may delay or limit Cytokinetics' or
its partners' ability to conduct clinical trials,
and Cytokinetics may be unable to obtain or maintain
patent or trade secret protection for its intellectual
property; Cytokinetics may incur unanticipated research
and development and other costs or be unable to obtain additional
financing necessary to conduct development of its products;
standards of care may change, rendering Cytokinetics' drug
candidates obsolete; and competitive products or alternative
therapies may be developed by others for the treatment of
indications Cytokinetics' drug candidates and potential
drug candidates may target. For further information regarding these
and other risks related to Cytokinetics' business,
investors should consult Cytokinetics' filings with
the Securities and Exchange Commission. Forward-looking
statements are not guarantees of future performance,
and Cytokinetics' actual results of operations, financial
condition and liquidity, and the development of the industry in
which it operates, may differ materially from the forward-looking
statements contained in this press release. Any forward-looking
statements that Cytokinetics makes in this press release
speak only as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024